Across TCGA pan-cancer cohorts, KTI12 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KTI12 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KTI12 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated KTI12 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where KTI12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.103	0.951	.024	10	view →
HNSC	DFS	Quartile	IV	0.420	0.821	.005	4	view →
LUAD	DFS	Quartile	All	0.573	1.000	.031	4	view →
LSCC	DFS	Median	II,III,IV	0.873	0.680	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: KTI12 tumor-vs-normal RNA expression · all KTI12 data types